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Abstract
In Spain, Leishmania infantum is endemic, human visceral and cutaneous leishmaniasis
cases occurring both in the Peninsula, as well as in the Balearic Islands. We aimed to de-
scribe the clinical characteristics of leishmaniasis patients and the changes in the disease
evolution after the introduction of antiretroviral therapy in 1997. In this descriptive study, we
used Spanish Centralized Hospital Discharge Database for the hospitalized leishmaniasis
cases between 1997 and 2011. We included in the analysis only the records having leish-
maniasis as the first registered diagnosis and calculated the hospitalization rates. Disease
trend was described taking into account the HIV status. Adjusted odds-ratio was used to es-
timate the association between clinical and socio-demographic factors and HIV co-infection.
Of the total 8010 Leishmaniasis hospitalizations records, 3442 had leishmaniasis as first di-
agnosis; 2545/3442 (75.6%) were males and 2240/3442 (65.1%) aged between 14-65
years. Regarding disease forms, 2844/3442 (82.6%) of hospitalizations were due to visceral
leishmaniasis (VL), while 118/3442 (3.4%) hospitalizations were cutaneous leishmaniasis
(CL). Overall, 1737/2844 of VL (61.1%) were HIV negatives. An overall increasing trend
was observed for the records with leishmaniasis as first diagnosis (p=0.113). Non-HIV leish-
maniasis increased during this time period (p=0.021) while leishmaniasis-HIV co-infection
hospitalization revealed a slight descending trend (p=0.717). Leishmaniasis-HIV co-infec-
tion was significantly associated with male sex (aOR=1.6; 95% CI: 1.25-2.04), 16-64 years
age group (aOR=17.4; 95%CI: 2.1-143.3), visceral leishmaniasis aOR=6.1 (95%CI:
3.27-11.28) and solid neoplasms 4.5 (95% CI: 1.65-12.04). The absence of HIV co-infection
was associated with lymph/hematopoietic neoplasms (aOR=0.3; 95%CI:0.14-0.57), other
immunodeficiency (aOR=0.04; 95% CI:0.01-0.32) and transplant (aOR=0.01; 95%CI:0.00-
0.07). Our findings suggest a significant increase of hospitalization in the absence of HIV
co-infection, with a predomination of VL. We consider that clinicians in Spain should be
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aware of leishmaniasis not only in the HIV population but also in non HIV patients, especial-
ly for those having immunosuppression as an associate condition.
Author Summary
Leishmaniasis is one of the most important human neglected parasitic diseases worldwide.
Although it is considered a disease of the developing world, it is currently spreading north-
wards, outbreaks are occurring in endemic areas, and foci of the disease are appearing in
previously non endemic countries, not necessarily associated to HIV as it occurred in the
past. In the Old World, the disease has two clinical forms, cutaneous and visceral leish-
maniasis. While the cutaneous form is mostly asymptomatic, the visceral form implies var-
ious degrees of severity, also being historically associated and influenced by the HIV co-
infection. Since 1997, antiretroviral therapy (ART) became available for HIV treatment,
subsequently influencing the evolution and epidemiology of leishmaniasis. In this paper
we use hospitalized leishmaniasis discharge data, in order to describe this disease´s geo-
graphical and temporal trends and its main epidemiological characteristics by patients´
HIV status since ART introduction, in Spain between 1997 and 201.
Introduction
Leishmaniasis represents a complex of mammalian diseases caused by parasitic protozoans
classified as Leishmania species and spread through the bite of the sand fly. Two major clinical
forms are known: cutaneous leishmaniasis (CL), causing scars and eventually disfiguration,
and systemic or visceral leishmaniasis (VL) that can lead to deadly complications if left untreat-
ed [1]. Worldwide, at least 20 Leishmania species are causing leishmaniasis. Most foci occur in
the tropics or subtropics, and only zoonotic L. infantum is transmitted in both the Old and the
NewWorld. L. infantum is the causative agent of both the cutaneous and visceral forms of
leishmaniasis in Southwest Europe [2].
This zoonotic-vector-borne disease has a proven complex transmission dynamic; the sea-
sonality of the vector species directly affects the transmission of the disease while the length of
the activity period and sand fly densities are influenced by the climate conditions that affect
their life cycle [3]. Moreover, the impacts of the sex, breed, age, use and habitat of the host dog
on the emergence of this disease have been also explored in several epidemiological surveys [4].
In Spain, leishmaniasis is endemic in most of the Iberian Peninsula and the Balearic Islands.
Two vector species are circulating, P. pernicious and P. ariasi [5]. Phlebotomus sergenti, the
main vector of Leishmania tropica, is also represented in Spain, whilst L. tropica is not an en-
demic species in this country [4]. The dog is the main domestic reservoir, although wild mam-
mals have been found infected with L. infantum [6]. Occasionally, outbreaks might occur.
From the mid-1980s to the late 1990s, a progressive increase in the number of cases of VL
was observed in Spain, mainly due to the HIV pandemic [7]. At that time, one of the major
challenges in controlling VL was its interaction with HIV infection, which increased the risk of
developing active VL by 100 to 2320 times [1]. Most of the Leishmania/HIV co-infected cases
occurred in medium age adult males, the disease presented mainly as VL [8]. These figures
were obtained at a time when only a handful of weak HIV drugs existed. Since the introduction
of highly active antiretroviral therapy (HAART) in January 1997, the number of Leishmania/
HIV co-infections decreased to less than 10 cases in 2008 [7], also lowering the number of
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relapses and associated mortality [9]. This could be explained by the relatively good health con-
dition of HIV patients treated with HAART but also because of an increased prescription of
Amphotericin B, a treatment with less side effects than toxic antimonials [9]. However, VL and
HIV co-infection has also been characterized by significantly lower cure rates, higher rates of
drug toxicity, and higher relapse and mortality rates when compared with HIV-negative VL
patients [10].
Currently, there is no national leishmaniasis control strategy in Spain, although some vecto-
rial and reservoir control measures are periodically implemented in several Autonomous com-
munities [5]. There are two main sources of information on human leishmaniasis
epidemiology in Spain: the Spanish Centralized Hospital Discharge Database (CMBD, in Span-
ish) and the National Epidemiological Surveillance Network (RENAVE, in Spanish). Both da-
tabases have been previously analyzed [5,9,11]. However, epidemiological changes in terms of
leishmaniasis patients’ characteristics and temporal trend after the introduction of HAART
have not been thoroughly assessed. Therefore, this study aims to describe the hospital admis-
sions and patients’ characteristics related to leishmaniasis disease and to assess the impact that
recent changes on HIV epidemiology might have had on the epidemiology of human leishman-
iasis in Spain.
Methods
A retrospective descriptive study was conducted using the CMBD, which is a national hospital
admission database managed by the Ministry of Health and Social Policy that includes all hos-
pitalizations and where diagnoses are coded according to the Spanish version of the Interna-
tional Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) [12]. The
CMBD registry includes encrypted patient administrative and clinical data. It receives notifica-
tion from around 98% of the public hospitals in Spain. Compulsory health insurance covers an
estimated 99.5% of the registered Spanish population, although persons not covered by health
insurance can receive treatment in public hospitals. Since 2005, CMBD also has a gradual cov-
erage from private hospitals [13].
All hospital discharges for leishmaniasis (ICD 9 CM 085.0–085.9; in any diagnostic posi-
tion) reported during a 15-year period (January 1, 1997 through December 31, 2011) were col-
lected. A hospitalization was defined as each discharge medical record entered in the CMBD.
For each entry, the following data were collected: sex, date of birth, autonomous community of
residence, admission date, type of discharge, length of stay, diagnosis and health conditions
other than leishmaniasis, surgical intervention during the stay and socioeconomic variables
(institutionalization and lack of resources). Age was categorized in three groups: 0–15, 16–64
and 65 years old. These three age categories were selected to provide an overview of children,
the working population and seniors. Days of stay in the hospital was categorized in 15 and
> 16 days.
The diagnosis and health conditions collected were other related factors and underlying
conditions for symptomatic leishmaniasis. These conditions were assessed by a search of all
those codes associated with leishmaniasis occurrence and included: neoplasia, immunodefi-
ciency other than HIV, transplantation and transplant failure, aplastic anemia, diabetes melli-
tus, hepatitis and long term use of steroids or other drugs (see S1 Text). ICD-9-CM codes 042
(HIV type 1), 079.53 (HIV type 2), V08 (asymptomatic HIV), and 795.71 (HIV nonspecific se-
rological evidence) corresponding to HIV infection, in any diagnostic position, were computed
as HIV-positive for analysis purposes.
The average number of hospitalizations per year and annual hospital admissions rate (per
1 million population) were calculated. Population at risk was obtained from the Spanish census
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projection [14]. It was assumed that the age distribution of the population covered by these
hospitals was similar to the general population. Hospitalization rates were computed by region
and year in order to assess temporal and geographical patterns. Results in terms of median
rates were plotted in maps for the whole study period. Trends in hospitalization rates were ana-
lyzed by linear regression.
Differences in proportions were assessed by the χ2 test and 95% confidence intervals (95%
CI) were calculated. Where a cell value was below 5, Fisher’s exact test for two-way tables was
applied. Student's t test was used to compare differences in means. We used two-sided tests
and p< 0.05 was considered significant.
Risk factors for leishmaniasis hospitalization were explored and stratified by HIV diagnosis,
using bivariate analysis. Independent variables significantly associated with leishmaniasis hos-
pitalization (p<0.1) were included in a forward stepwise multiple logistic regression model.
Adjusted odds-ratio (aOR) and 95% confidence intervals were estimated. Where cell values
were 0, 1 was added to each cell. The major assumptions of logistic regression analysis (absence
of multicollinearity and interaction among independent variables) were checked to be satisfied.
The goodness of fit of logistic regression models was assessed using Hosmer-Lemeshow statis-
tic. We used PASW version 18.0 (SPSS Inc., Chicago, IL) and Arcgis version 10.0 software for
data analysis.
Ethics Statement
This study involves use of patient medical data from The Spanish National Hospital Database
(CMBD). These data are hosted by the Ministry of Health Social Services and Equality
(MSSSI). Researchers working in public and private institutions can request the databases by
filling, signing and sending a questionnaire available at the MSSSI website. In this question-
naire a signed Confidentiality Commitment is required. All data is anonymized and de-identi-
fied by the MSSII before it is provided to solicitants.
Table 1. Descriptive analysis of leishmaniasis related hospitalizations, 1997–2011, Spain.
Variable Related
hospitalizations
(n = 8010)
Leishmania as
ﬁrst diagnosis (n
= 3442)
N % N %
Sociodemographic characteristics
Sex Female 1653 20.6 897 26.1
Male 6357 79.4 2545 75.6
Age group 0–15 930 11.6 820 23.8
16–64 6461 80.7 2240 65.1
65 619 7.7 382 11.1
Clinical characteristics
Clinical form of leishmaniasis Cutaneous 225 2.8 118 3.4
Visceral 6447 80.5 2844 82.6
Non-deﬁned 1338 16.7 480 13.9
HIV status Positive 5079 63.40 1255 36.46
Negative 2931 36.60 2187 63.54
doi:10.1371/journal.pntd.0003594.t001
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Results
Spatial and temporal trends in Spain
A total of 8010 hospital discharges with diagnosis of leishmaniasis in any position were identi-
fied for the 15-year study period. Leishmaniasis diagnosis alone (without other diagnoses) oc-
curred in 538 hospitalizations (6.7%), out of which 422 (78.4%), 24 (4.5%) and 92 (17.1%) were
VL, CL and non-defined related forms, respectively. In 3442/8010 (42.8%) hospitalizations,
leishmaniasis was registered as first diagnosis and further considered for the analysis; 2545/
3442 (75.6%) were males, 2240/3442 (65.1%) belonged to the 14–65 age group.
Regarding the clinical form of leishmaniasis, 2844/3442 (82.6%) of hospitalizations were
due to visceral leishmaniasis (VL), only 118/3442 (3.4%) hospitalizations were cutaneous leish-
maniasis (CL), while 480/3442 (14.3%) were admitted as undetermined forms. For the whole
database, which included leishmaniasis diagnosis in any position, similar figures were obtained:
6447/8010 (80.5%) VL, 225/8010 (2.8%) CL and 1338/8010 (16.7%) undetermined form. The
distribution according to the age was slightly different, with a higher proportion of the 16–64
age group for the whole database than for those hospitalizations with leishmaniasis as first di-
agnosis. The percentage of HIV positive increased from 36.5% to 63.4% when we asses only
those hospitalizations with leishmaniasis as first diagnosis and the whole database, respectively
(Table 1).
The temporal distribution of hospitalizations related to leishmaniasis as first diagnosis dur-
ing the 15-year study period is represented in Fig. 1. At the national level, the median annual
hospitalization rate was 5.6/1 million population (range 3.2–6.6/1 million population). The
median annual hospitalization rate for hospitalized leishmaniasis-HIV co-infection was 1.9
(range 1.5 to 2.5), while for leishmaniasis hospitalizations without an HIV diagnosis was 3.4/1
million population (range 1.7 to 4.7). From 1997 to 2011, an increasing trend in the rates of
hospitalizations with leishmaniasis as first diagnosis was observed (p = 0.113). Non-HIV leish-
maniasis has also increased during this time period (p = 0.021) while leishmaniasis-HIV co-
infection hospitalization revealed a slight descending trend (p = 0.717). These trends were simi-
lar to those observed when assessing all leishmaniasis related hospitalizations (n = 8010), with
exception to the trend for the total population (regardless the HIV status), which shown a
slightly descending trend (S1 Fig).
Regarding the distribution of leishmaniasis hospitalizations (as first diagnosis) throughout
the whole study period, the Madrid region had the highest median hospitalization rate (10.3
hospitalizations/1 million population), followed by the Balearic Islands (7.2/1 million popula-
tion), Valencia (7.4/1 million population), Aragon (6.8/1 million population) and Castilla La
Mancha (6.4/1 million population). The Northern autonomous communities of Spain (Canta-
bria, Navarra, Basque Country and Galicia) were among the ones with lower leishmaniasis hos-
pitalization rates (S1 Table). The highest differences between leishmaniasis alone and
leishmaniasis-HIV co-infection were registered in Castilla La Mancha, Catalonia and Murcia.
Interestingly, Aragon was the only region where leishmaniasis-HIV co-infection hospitaliza-
tion rate was higher than leishmaniasis alone (Fig. 2).
The hospitalization trends within the regions with higher rates revealed different patterns. In
Castilla La Mancha, hospitalization rates peaked in 2001 and were afterwards followed by a
steady decline. The same decreasing trend was observed in Valencia. In the Balearic Islands, the
hospitalization rate periodically reached high values during 2004, 2006 and 2009. A similar trend
was identified in Aragon. In Madrid, after a significant increase (p = 0.01), a pick was reached to-
wards the end of the study period, in 2011. The same tendency was identified in Andalusia (p =
0.05) while the Basque Country was the only region with a significant decrease in hospitalization
rate (p = 0.042). The rest of the regions did not show significant tendencies (Fig. 3).
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Difference between leishmaniasis and leishmaniasis-HIV co-infection
cases
In all leishmaniasis as first diagnosis hospitalization cases, information on HIV status was
available. Of them, 1255/3442 (36.4%) were HIV positive. The proportion of males was higher
among HIV positives compared to HIV negatives, 1084/1255 (86.4%) and 1461/2187 (66%),
respectively. Nearly all HIV positives belonged to the 16–64 age group, 1248/1255 (99.4%),
compared to 992/2187 (45.4%) of HIV negatives (Table 2).
Visceral leishmaniasis was the predominant clinical form both in HIV positives 1107/1255
(88.2%) and in HIV negatives 1737/2187 (79.4%). The most frequent co-morbidities docu-
mented in the HIV positive group were aplastic anemia 177/1255 (14.1%), hepatitis 143/1255
(11.4%) and alcoholism 72/1255 (5.7%). There was a history of surgery in 70/1255 (5.6%) and
of institutionalization in 108/1255 (8.6%) of HIV positive records. In the HIV negative group,
the most frequent comorbidities or conditions were aplastic anemia, history of surgery and dia-
betes with 331/2187 (15.1%), 193/2187 (8.8%) and 177/2187 (8.1%) records, respectively
(Table 2).
Leishmaniasis hospitalization with HIV co-infection was significantly associated with male
sex, (aOR = 1.6 (95% CI 1.25–2.04)), and age group 16–64 years (aOR = 17.4 (95%CI 2.1–
143.3)). Regarding the disease outcome, patients hospitalized with HIV co-infection where 1.3
times more likely to decease, compared to hospitalized patients without HIV infection (95%CI
0.9–1.96). The hospitalized individuals with leishmaniasis HIV co-infection were also 6 times
more likely to have visceral leishmaniasis compared with those without HIV infection, and 4
times more likely to have a solid neoplasm diagnosis. They were also 4 times more likely to
Fig 1. Temporal trend of hospitalizations with leishmaniasis as first diagnosis rates by HIV status, 1997–2011, Spain.
doi:10.1371/journal.pntd.0003594.g001
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have a positive hepatitis diagnosis. Institutionalization and a history of long term drug use
were significantly associated with hospitalization with Leishmania HIV co-infection. The hos-
pitalization period did not differ between HIV co-infected leishmaniasis hospitalizations and
non HIV leishmaniasis hospitalizations, and predominantly lasted less than 2 weeks (Table 2).
Discussion
This study provides a 15-year review of the epidemiological trends and patient characteristics
of Leishmania hospitalizations in Spain. We particularly covered all the antiretroviral therapy
era since 1997 and stratified the results by HIV status. The CMBD database provides a reliable
picture of the Spanish leishmaniasis related hospitalization as it covers 98% of public hospital´s
admissions. Public healthcare insurance is covering almost 100% of the Spanish population as
of 2011, and private hospitals represent only a small proportion of all hospital admissions [15].
During this 15-year period, there were 8010 hospitalizations for which leishmaniasis codes
were entered in any diagnostic position among which 3442 records had leishmaniasis codes in
the first position. The majority of the overall hospitalizations belonged to the 16–64 age group
and this could be regarded as within the general tendency of hospitalizations in Spain. On the
other hand, within the hospitalizations due to leishmaniasis as first diagnosis, the higher per-
centage of the 0–15 years age group compared to the overall hospitalization group could be
seen as due to the disease’s characteristics [5]. However, given the similarities between both
groups for the other main characteristics and because readmissions could not be clearly
Fig 2. Median rates of hospitalizations with leishmaniasis as first diagnosis for HIV and non HIV leishmaniasis by autonomous community, Spain,
1997–2011.
doi:10.1371/journal.pntd.0003594.g002
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identified with the database, we decided to consider for further analysis only the 3442 records
were leishmaniasis was the first diagnosis. As in previous studies that have used the CMBD, we
assumed that the first diagnosis was the cause of admission [5,9,11].
It is generally admitted that, worldwide, the true burden of leishmaniasis disease is underes-
timated [16]. In Spain, leishmaniasis was declared a notifiable disease from 1982 to 1995. Since
1996, a new decentralized surveillance system (RENAVE) was implemented and leishmaniasis
became a notifiable disease in those regions where it is considered endemic (12 out of 17 auton-
omous communities: Andalucía, Aragón, Baleares, Cantabria, Castilla-León, Cataluña, Valen-
cia, Extremadura, Madrid, Murcia, Navarra and La Rioja) [5]. Between 1996 and 2011,
RENAVE detected 1755 leishmaniasis cases [5,9], almost half of CMBD records with leishman-
iasis codes in first position (3442 cases from 1997 to 2011). The difference in reported cases be-
tween the two systems clearly suggests that underreporting is an important aspect in Spain
with a non-negligible magnitude.
In our study, the geographical distribution shows that hospitalizations have been reported
from all over the country. Previous epidemiological reviews have also detected cases in all pen-
insular regions of Spain and the Balearic islands as well as a homogenization of the distribution
when considering the HIV co-infected cases [5,11]. Given this continued reporting from all re-
gions, the non-endemic condition of some regions should be reconsidered as should be the atti-
tudes towards strengthening the disease surveillance in these areas. According to RENAVE, the
regions with the highest incidence during 1996–2011 were Baleares, Valencia, Madrid, Andalu-
sia and Catalonia [5]. Although this geographical distribution seems similar to our figures, the
picture changes when we stratified by HIV status, Castilla La Mancha and Aragon placing sec-
ond in hospitalization rates for non-HIV and HIV co-infected cases, respectively. Several fac-
tors could be responsible for the differences in leishmaniasis hospitalization rates encountered
between autonomous regions. The distribution of HIV cases and related risk factors within
Fig 3. Median rates of Leishmaniasis hospitalizations with leishmaniasis as first diagnosis by autonomous community and year, in those
communities with up to 100 cases.
doi:10.1371/journal.pntd.0003594.g003
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Table 2. Differences among leishmaniasis and co-infected leishmaniasis-HIV cases based hospitalizations, with leishmaniasis as ﬁrst
diagnosis. Spain 1997–2011
Variables Leishmania as ﬁrst diagnosis (n = 3442)
VIH positive VIH negative Unadjusted OR Adjusted OR
N % N %
No. of subjects 1255 36.46 2187 63,54
Sex Female 171 13.6 726 33.2 1 1
Male 1084 86.4 1461 66.8 2.22 (1.93–2.56)** 1.50 (1.17–1.91) *
Age group 0–15 0 0.0 820 37.5 1 1
16–64 1248 99.4 992 45.4 1032 (144.9–7344) ** 990 (138.76–7065.63) **
>65 7 0.6 375 17.1 0.07 (0.01–0.53) ** 0.02 (0.01–0.03) **
Leishmaniasis Cutaneous 13 1.0 105 4.8 1 1
Visceral 1107 88.2 1737 79.4 5.15 (2.88–9.20) ** 6.07 (3.27–11.28) **
Non-deﬁned 135 10.8 345 15.8 0.32 (0.18–0.60) ** 0.06 (0.06–0.77) **
Type of discharge No Exitus 1252 94.3 2042 96.5 1 1
Exitus 48 3.6 59 2.8 1.33 (0.90–1.96) –
Unknown 27 2.0 14 0.7 3.14 (1.64–6.02) ** 4.18 (1.50–11.66) *
Re-hospitalization No 887 70.7 1732 79.2 1 1
Yes 368 29.3 455 20.8 1.56 (1.35–1.85) ** 1.69 (1.35–2.12) **
Surgery No 1185 94.4 1994 91.2 1 1
Yes 70 5.6 193 8.8 0.61 (0.46–0.81) ** 1.75 (1.24–2.47) **
Days of stay 15 days 852 67.9 1486 67.9 1 –
> 16 days 403 32.1 701 32.1 1 (0.86–1.16) –
Solid neoplasm No 1230 98.0 2165 99.0 1 1
Yes 25 2.0 22 1.0 2 (1.12–3.56)* 4.45 (1.65–12.04) *
Lymph- hematopoietic neoplasms No 1246 99.3 2132 97.5 1 1
Yes 9 0.7 55 2.5 0.28 (0.14–0.57) ** 0.25 (0.11–0.57) *
Other immunodeﬁciencies No 1255 99.9 2149 98.3 1 1
Yes 1 1.0 37 1.7 0.05 (0.01–0.34) ** 0.04 (0.01–0.32) *
Transplant No 1255 100.0 2098 95.9 1 1
Yes 0 0.0 89 4.1 0.01 (0.01–0.14) ** 0.01 (0.00–0.07) **
Transplant failure No 1245 99.2 2160 98.8 1 –
Yes 10 0.8 27 1.2 0.64 (0.31–1.33) –
Aplastic Anemia No 1078 85.9 1856 84.9 1 –
Yes 177 14.1 331 15.1 0.92 (0.76–1.12) –
Diabetes Mellitus No 1244 99 2009 91.9 1 1
Yes 12 1 177 8.1 0.11 (0.06–0.20) ** 0.10 (0.05–0.18) **
Hepatitis No 1112 88.6 2153 98.4 1 1
Yes 143 11.4 34 1.6 8.14 (5.56–11.92) ** 3.95 (2.52–6.20) **
Long term use of steroids No 1255 100.0 2171 99.3 1 1
Yes 0 0.0 16 0.7 0.11 (0.01–0.81) * 0.69 (0.05–9.65)
Long-term drug use No 1219 97.1 2168 99.1 1 1
Yes 36 2.9 19 0.9 3.37 (1.92–5.19) ** 2.97 (1.40–6.33) *
Alcoholism No 1183 94.3 2143 98.0 1 1
Yes 72 5.7 44 2.0 2.96 (2.02–4.34) ** 1.76 (1.12–2.78) *
Institutionalized No 1147 91.4 2169 99.2 1 1
Yes 108 8.6 18 0.8 11.35 (6.85–18.78) ** 3.96 (2.27–6.91) **
(Continued)
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different autonomous regions could be playing a role in the differences on hospitalizations
rates [17]. On the other hand, the epidemiological characteristics of Leishmania and HIV co-
infection can differ from one autonomous community to another due to parasite strain and
other differences in aetiological agent circulation (involving parasite, host and reservoir), vec-
tor behaviour [3] and, possibly, associated regional geographic and climatic factors or socio-en-
vironmental conditions of the exposed hosts [18].
We have found an increasing trend in leishmaniasis as first diagnosis hospitalization rates
from 1997 to 2011, although this trend was statistically significant only for non-HIV cases.
Moreover, the analysis of the temporal distribution of leishmaniasis hospitalization rates in
Spain shows an endemic pattern with increases every 3–4 years, suggesting the existence of lo-
calized outbreaks. It is during these “peaks” when the differences in figures encountered by
HIV-status seem greater. Looking at the temporal distribution by autonomous regions (Fig. 3),
we can observe that this increasing trend occurs mainly at the expense of the community of
Madrid, where one of the most important Leishmaniasis outbreaks in Europe, starting from
2010, has taken place. According to Arce et al., in this outbreak, only 4% of all leishmaniasis
cases were coinfected with HIV [19]. The risk of Leishmania onset for HIV infected persons
during a Leishmania outbreak is unclear and must probably depend on the HIV-status and ad-
herence treatment. Further research is needed to clarify this issue.
Other trends and peaks, like those in Andalusia, also suggest the existence of outbreaks but
there are no literature referrals describing such outbreaks. It would therefore be required to
carry out retrospective analyses to better characterize these possible outbreaks using the data
available at the national epidemiological network (RENAVE). This would provide valuable in-
formation and would help add new knowledge about the epidemiological picture of leishmani-
asis in Spain.
Regarding the characteristics of the cases registered as Leishmaniasis as first diagnosis, pa-
tients were predominantly male, belonging to the age group 16–64 years and admitted for vis-
ceral leishmaniasis. This patient profile has constantly been identified in previous studies and
the predominance of visceral leishmaniasis is related to the hospitalization-based data source
[9,11]. HIV stratification slightly reduces the differences between sexes and age groups
(Table 2). Thus, age group 0–14 accounts for more than 30% of records among HIV negatives
while there were no records for this age group among HIV positives. However, males are still
largely prevalent in HIV negatives, which seems to be concordant with findings from previous
epidemiological studies indicating that VL occurs more frequently among adult males [20]. Al-
though the role of sex hormones has been hypothesized in the modulation of immunity against
leishmaniasis [21,22], the explanation for this trend still remains uncertain.
Table 2. (Continued)
Variables Leishmania as ﬁrst diagnosis (n = 3442)
VIH positive VIH negative Unadjusted OR Adjusted OR
N % N %
Lack of resources No 1245 99.2 2183 99.8 1 1
Yes 10 0.8 4 0.2 4.38 (1.37–14.03) * 4.53 (0.84–24.46)
* p<0.05;
** p<0.001.
doi:10.1371/journal.pntd.0003594.t002
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As can be observed in Table 2, stratification by HIV status proves to be a very helpful meth-
od to further characterize leishmaniasis hospitalizations. Significant differences were observed
for most of the variables included in the analysis, notably solid neoplasm, hepatitis, long term
drug use, alcoholism, institutionalization and lack of resources, all of them more likely to be
present in HIV hospitalized patients. Interestingly, non HIV hospitalized patients were more
likely to present other conditions such as lymphohematopoietic neoplasms, immunodeficiency,
transplantation, diabetes mellitus and long term use of steroids. It is well-known that malnutri-
tion and immunosuppression may reactivate latent Leishmania infection, thus becoming risk
factors particularly for the visceral form [23]. However most research has been focused in ac-
quired immunodeficiency [21].
In HIV co-infected cases, the literature shows that cure trends are lower and relapse rates
and mortality are higher, when compared to non HIV leishmaniasis patients [10]. In our study,
HIV co-infection was not significantly associated with higher mortality. This supports findings
in previous studies where no difference in mortality could be found in the HIV leishmaniasis
co-infected patients group compared to leishmaniasis without HIV [9]. However, another sim-
ilar paper revealed a significant association between HIV co-infection and higher mortality
[11]. It is also interesting to highlight the fact that the average hospitalization length was under
2 weeks in two thirds of hospitalizations in both HIV and non HIV cases. This could be ex-
plained by an extended use of amphotericin B reflecting the efficacy of the drug together with
the reduced toxicity [9]. On the contrary, the high and significant OR found for the two vari-
ables analysing socioeconomic factors suggest that these still play a major role in the HIV pop-
ulation vulnerability to leishmaniasis. Further investigation is needed in order to confirm or
dismiss this association in the highly active antiretroviral therapy era.
Limitations and conclusions
The CMBD does not provide information about parasite isolation, detection, PCR or serologic
test for diagnosis of visceral leishmaniasis (VL). However, the CMBD database provides reli-
able information to support decision-making based on ICD-9 codification carried out by medi-
cal doctors. It has been proved to be a trusted source for many epidemiological studies
[9,11,24]. Leishmaniasis is endemic in Spain. Diagnosis is not performed on primary health
care level, but in hospitals [25]. Human leishmaniasis diagnosis fits the case definition criteria
given by WHO: “a case of visceral leishmaniasis is a person showing clinical signs (mainly pro-
longed irregular fever, splenomegaly and weight loss), with serological and/or parasitological
confirmation” [1]. As common practice, in Spanish hospitals the diagnosis of VL is mainly
based on the bone marrow aspirate, either by direct microscopy visualization or PCR detection
[25]. CMBD database does not reveal the exact number of patients who have been diagnosed
with other techniques, such as serology, but it is probably small.
The CMBD provides a complete record of all hospitalizations and is not subject to the limi-
tations of outpatient surveillance systems. Still, the CMBD does not show the real incidence of
Leishmania infection, as cutaneous infections are mainly treated in primary care centers and
not entered in this registry [9]. Another limitation of the CMBD is that data is anonymous so it
is not possible to confirm if the same patient was admitted more than once in different calendar
years. Furthermore, it is not possible to identify admission of the same patient to
different hospitals.
Since highly active antiretroviral therapy was introduced in 1997, a decrease in the number
of leishmaniasis cases might have been expected. However, a significant decrease has only been
reported for co-infected cases [10]. On the other hand, leishmaniasis is currently spreading
northwards in endemic regions, outbreaks are occurring in endemic areas, and foci of the
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disease are appearing in previously non endemic European countries [2,10]. Similarly to previ-
ous papers [9,11], we have observed a change in the epidemiology of VL hospitalizations, with
the increase of non-HIV VL cases. This can have direct clinical implications. Classically, VL in
Spain has been associated to the HIV epidemic and clinicians regularly consider this diagnosis
in HIV patients presenting compatible clinical signs and symptoms [7,22,26]. However, the
findings of the present study show a changing clinical pattern with other co-morbidities. This
requires a special clinical consideration for several reasons; for example, the increased numbers
of subjects receiving therapy for autoimmune diseases, cancer or transplants that result in sup-
pressed cellular immunity [10,23], as is the disease burden of diabetes mellitus type 2 [27] and
other prevalent co-morbidities in the Spanish population [28], probably playing a role in the
progression to symptomatic leishmaniasis. Moreover, there is limited awareness of the disease
among clinicians other than those treating infectious diseases. In conclusion, we consider that
clinicians in Spain should be aware of leishmaniasis not only in the HIV population but also in
non HIV patients and particularly in those presenting the above referred comorbidities.
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